Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 9/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24914704 | 1.00 | CLPP (0.50) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24914395 | 0.94 | CLPP (0.55) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24914413 | 0.93 | CLPP (0.49) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL30130122 | 0.93 | CLPP (0.49) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24915135 | 0.93 | CLPP (0.49) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24914793 | 0.92 | CLPP (0.50) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24914794 | 0.92 | CLPP (0.50) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24915132 | 0.91 | DDB1 (0.49) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL24915123 | 0.91 | ENPP2 (0.50) | CLPPDDB1CRBNENPP2MEN1 | |
| SCHEMBL30130156 | 0.91 | DDB1 (0.49) | CLPPDDB1CRBNENPP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | claimed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | claimed |
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | CLPP 7/4885DDB1 3529/4885CRBN 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.